ProKidney Corp. (PROK) Stock

ProKidney Corp. (PROK) is a Healthcare stock trading at $1.82 (as of 2026-06-18), with a market capitalization of $375.52M and a trailing P/E of -5.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ProKidney Corp. is a clinical-stage biotechnology company developing cellular therapy candidates. Its pipeline includes an autologous renal cell therapy in Phase III development and additional clinical studies in diabetic kidney disease and congenital anomalies of the kidney and urinary tract.

Valuation — source: SEC EDGAR (first-party)

Price	$1.82
Market Cap	$375.52M
P/E Ratio	-5.2
EV / EBITDA	-1.7
Price / Book	-0.37
Price / Sales	422.40
DCF Value (model)	$-35.67
DCF Upside vs Price	-2054.5%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$893000.00
Net Margin	-7725.2%
Return on Equity	7.1%
Current Ratio	9.06
Revenue Growth (YoY)	-1.7%
FCF Growth (YoY)	48.0%

Financial Health — source: SEC EDGAR

Altman Z-Score

-5.97 (distress)

Valuation vs Sector & Industry

Stock P/E	-5.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-124.9%
vs Industry	-130.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	SUVRETTA CAPITAL MANAGEMENT, LLC ($22.09M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Bruce Culleton
Employees	204
Country	US
IPO Date	2021-06-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• SIGA Technologies, Inc. (SIGA)
• Evolus, Inc. (EOLS)
• 4D Molecular Therapeutics, Inc. (FDMT)
• DiaMedica Therapeutics Inc. (DMAC)
• Akebia Therapeutics, Inc. (AKBA)
• Ocugen, Inc. (OCGN)
• Lexicon Pharmaceuticals, Inc. (LXRX)
• Kamada Ltd. (KMDA)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.